Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Neurochemistry

• Publication date

  2001-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/j.1471-4159.2001.00059.xPMID 11145989
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Motor disorder in Huntington's disease begins as a dysfunction in error feedback control

  2000cited by this paper
• Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models.

  2000cited by this paper
• Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation

  2000cited by this paper
• Membrane fusion and exocytosis.

  1999cited by this paper
• Brain Neurotransmitter Deficits in Mice Transgenic for the Huntington’s Disease Mutation

  1999cited by this paper
• A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

  1999cited by this paper
• Impaired synaptic plasticity in mice carrying the Huntington's disease mutation.

  1999cited by this paper
• Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation

  1999cited by this paper
• Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington’s Disease Mutation

  1999cited by this paper
• Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice.

  1999cited by this paper
• Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone.

  1999cited by this paper
• Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease.

  1999cited by this paper
• Immunohistochemical distribution of the two isoforms of synaphin/complexin involved in neurotransmitter release: localization at the distinct central nervous system regions and synaptic types.

  1999cited by this paper
• Reduced hippocampal LTP in mice lacking a presynaptic protein: complexin II

  1999influential reference
• Characterization of the mouse Src homology 3 domain gene Sh3d2c on Chr 7 demonstrates coexpression with huntingtin in the brain and identifies the processed pseudogene Sh3d2c-ps1 on Chr 2.

  1998cited by this paper
• Huntington disease.

  1998cited by this paper
• Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice.

  1998cited by this paper
• Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

  1998cited by this paper
• Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways.

  1998cited by this paper
• Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia.

  1998cited by this paper
• Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 Å resolution

  1998cited by this paper
• Evidence for specific cognitive deficits in preclinical Huntington's disease.

  1998cited by this paper
• Regulatory roles of complexins in neurotransmitter release from mature presynaptic nerve terminals

  1997cited by this paper
• Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

  1997cited by this paper
• Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.

  1997influential reference
• Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse.

  1997cited by this paper
• Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

  1996influential reference
• A Novel Function for the Second C2 Domain of Synaptotagmin

  1996cited by this paper
• A huntingtin-associated protein enriched in brain with implications for pathology

  1995influential reference
• Cognitive scores in carriers of huntington's disease gene compared to noncarriers

  1995cited by this paper
• Complexins: cytosolic proteins that regulate SNAP receptor function.

  1995cited by this paper
• Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons.

  1995influential reference
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• Clinical and neuropathologic assessment of severity in Huntington's disease

  1988cited by this paper
• INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY

  1976cited by this paper

• Pathological and Functional Brain Amyloids: A New Concept Explaining the Differences

  2025cites this paper
• Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington’s disease

  2025cites this paper
• Polyglutamine Expansion in Huntingtin and Mechanism of DNA Damage Repair Defects in Huntington’s Disease

  2022cites this paper
• Dysfunction of the SNARE complex in neurological and psychiatric disorders.

  2021cites this paper
• Super-resolution imaging reveals extrastriatal synaptic dysfunction in presymptomatic Huntington disease mice.

  2021cites this paper
• Do Changes in Synaptic Autophagy Underlie the Cognitive Impairments in Huntington’s Disease?

  2021cites this paper
• Axonal ER Ca2+ Release Enhances Miniature, but Reduces Activity-Dependent Glutamate Release in a Huntington Disease Model

  2020cites this paper
• Hippocampal Synaptic Dysfunction in a Mouse Model of Huntington Disease Is Not Alleviated by Ceftriaxone Treatment

  2020cites this paper
• Early synaptic hippocampal deficits in the Q175FDN mouse model of Huntington Disease

  2019cites this paper
• Cortical circuit alterations precede motor impairments in Huntington’s disease mice

  2019cites this paper
• Cortical circuit alterations precede disease onset in Huntington’s disease mice

  2018cites this paper
• Studying Huntington’s Disease in Yeast: From Mechanisms to Pharmacological Approaches

  2018cites this paper
• Mutant Huntingtin Causes a Selective Decrease in the Expression of Synaptic Vesicle Protein 2C

  2018cites this paper
• Neuromuscular synapse degeneration without muscle function loss in the diaphragm of a murine model for Huntington's Disease

  2018cites this paper
• Global neuroprotection of huntingtin in culture and alterations of cortico-striatal connections in Huntington’s disease culture and mouse models

  2017influential citation
• Synaptopathic mechanisms of neurodegeneration and dementia: Insights from Huntington’s disease

  2017cites this paper
• Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets

  2017cites this paper
• Depressed Synaptic Transmission and Reduced Vesicle Release Sites in Huntington's Disease Neuromuscular Junctions

  2017cites this paper
• Impaired development of cortico-striatal synaptic connectivity in a cell culture model of Huntington's disease.

  2016cites this paper
• Changes in structure and function of diaphragm neuromuscular junctions from BACHD mouse model for Huntington's disease.

  2016cites this paper
• Neurobiology of Huntington's Disease.

  2015cites this paper
• Dysregulation of SIRT1 activity in the pathogenesis of Huntington's disease

  2015cites this paper
• Cholesterol‐loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice

  2015cites this paper
• Amyloid-β Oligomers May Impair SNARE-Mediated Exocytosis by Direct Binding to Syntaxin 1a.

  2015cites this paper
• Caractérisation of GABAergic neurotransmission within basal ganglia circuit in R6/1 Huntington's disease mouse model

  2014cites this paper
• Maintenance of chaperone-mediated autophagy activity in cultured cells expressing mutant huntingtin.

  2014cites this paper
• Dysregulation of REST‐regulated coding and non‐coding RNAs in a cellular model of Huntington's disease

  2013cites this paper
• Basal ganglia function in genetic mouse models of Huntington's disease: a circuit-level approach

  2013influential citation
• Synaptic function in the hippocampus in neurodegenerative disease

  2013cites this paper
• Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms

  2012cites this paper
• Validation of HDAC6 and SIRT2 tubulin deacetylases as therapeutic targets for Huntington's disease

  2012cites this paper
• In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease

  2011cites this paper
• Interneuron Cell Loss in the Human Cerebral Cortex in Huntington’s Disease

  2011cites this paper
• Synaptic Dysfunction in Huntington’s Disease

  2011cites this paper
• Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms.

  2011cites this paper
• Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse.

  2010cites this paper
• Diminished Activity-Dependent Brain-Derived Neurotrophic Factor Expression Underlies Cortical Neuron Microcircuit Hypoconnectivity Resulting from Exposure to Mutant Huntingtin Fragments

  2010cites this paper
• Glutamate‐induced alterations in Ca2+ signaling are modulated by mitochondrial Ca2+ handling capacity in brain slices of R6/1 transgenic mice

  2010cites this paper
• Calcium channel dysfunction in Huntington's disease

  2009cites this paper
• HSP40 Ameliorates Impairment of Insulin Secretion by Inhibiting Huntingtin Aggregation in a HD Pancreatic β Cell Model

  2009cites this paper
• The molecular pathogenesis of Huntington’s disease

  2009cites this paper
• [Pathophysiology of Huntington's disease: an update].

  2008cites this paper
• Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice.

  2008cites this paper
• Mechanisms of neurodegeneration in Huntington’s disease

  2008cites this paper
• Expanded-Polyglutamine Huntingtin Protein Suppresses the Secretion and Production of a Chemokine (CCL5/RANTES) by Astrocytes

  2008cites this paper
• REVIEW ARTICLE Mechanisms of neurodegeneration in Huntington's disease

  2008cites this paper
• Altered complexin expression in psychiatric and neurological disorders: cause or consequence?

  2008cites this paper
• Polyglutamine gene function and dysfunction in the ageing brain.

  2008cites this paper
• Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death.

  2008cites this paper
• Distinct domains of Complexin I differentially regulate neurotransmitter release

  2007cites this paper
• Towards understanding the schizophrenia code: An expanded convergent functional genomics approach

  2007cites this paper
• Transcriptional signatures in Huntington's disease.

  2007cites this paper
• Kinetics of complexin binding to the SNARE complex: correcting single molecule FRET measurements for hidden events.

  2007cites this paper
• SNAP-25 and Cdk5 as exocytotic regulators : Consequences for synaptic function and insulin release

  2007cites this paper
• The corticostriatal pathway in Huntington's disease.

  2007cites this paper
• Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.

  2007influential citation
• Integrative hypothesis for Huntington's disease: a brief review of experimental evidence.

  2007cites this paper
• Towards Understanding The Schizophrenia Code : An Expanded Convergent Functional Genomics Approach

  2007cites this paper
• Complexin 1 knockout mice exhibit marked deficits in social behaviours but appear to be cognitively normal.

  2007cites this paper
• Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease.

  2007cites this paper
• Selective extra-dimensional set shifting deficit in a knock-in mouse model of Huntington's disease.

  2006cites this paper
• Selective neuronal degeneration in Huntington's disease.

  2006cites this paper
• Early, Transient Increase in Complexin I and Complexin II in the Cerebral Cortex following Traumatic Brain Injury Is Attenuated by N-Acetylcysteine

  2006cites this paper
• Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease

  2006cites this paper
• Comparative proteomics in neurodegenerative and non-neurodegenerative diseases suggest nodal point proteins in regulatory networking.

  2006cites this paper
• Synaptic Abnormalities Associated with Huntington’s Disease

  2006cites this paper
• ETUDE DE L'AMPLIFICATION DE LA NEURODEGENERESCENCE EXCITOTOXIQUE PAR UNE DYSFONCTION MITOCHONDRIALE : IMPLICATIONS POUR LA MALADIE DE HUNTINGTON

  2006cites this paper
• Downregulation of complexin I and complexin II in the medial thalamus is blocked by N‐acetylcysteine in experimental Wernicke's encephalopathy

  2005cites this paper
• Profound ataxia in complexin I knockout mice masks a complex phenotype that includes exploratory and habituation deficits.

  2005cites this paper
• A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse

  2005cites this paper
• Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington’s disease is not improved by treatment with hypoglycaemic agents

  2005cites this paper
• The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies

  2005cites this paper
• Synaptic Alterations in Genetic Mouse Models of Huntington’s and Parkinson’s Diseases: Is there a Common Thread?

  2005cites this paper
• Complexin II facilitates exocytotic release in mast cells by enhancing Ca2+ sensitivity of the fusion process

  2005cites this paper
• Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction.

  2005cites this paper
• Dopamine et dégénérescence des neurones striataux dans la maladie de Huntington : vers l'identification de nouvelles cibles thérapeutiques

  2005cites this paper
• Dopamine and Glutamate in Huntington’s Disease

  2005cites this paper
• A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease

  2005cites this paper
• Synaptic dysfunction in Huntington’s disease: a new perspective

  2005cites this paper
• Differential messenger RNA expression of complexins in mouse brain.

  2004cites this paper
• Early changes in Huntington’s disease patient brains involve alterations in cytoskeletal and synaptic elements

  2004cites this paper
• Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation

  2004cites this paper
• Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect.

  2004cites this paper
• Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation.

  2004cites this paper
• Expression of Mutant Huntingtin Blocks Exocytosis in PC12 Cells by Depletion of Complexin II*

  2003cites this paper
• MECHANISMS OF POLYGLUTAMINE EXPANDED HUNTINGTIN INDUCED TOXICITY

  2003cites this paper
• Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease

  2003cites this paper
• Huntington's disease: a synaptopathy?

  2003cites this paper
• Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release.

  2003cites this paper
• Complexin II is essential for normal neurological function in mice.

  2003cites this paper
• Neural Transplantation in Patients with Huntington’s Disease

  2003cites this paper
• Mechanisms of transcriptional dysregulation in Huntington's disease

  2003cites this paper
• Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice

  2002cites this paper
• Inhibition of tryptophan hydroxylase activity and decreased 5‐HT1A receptor binding in a mouse model of Huntington's disease

  2002cites this paper
• Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice.

  2002cites this paper
• Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice.

  2002cites this paper
• Mouse models of Huntington's disease.

  2002cites this paper
• The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease

  2002cites this paper
• Three-dimensional structure of the complexin/SNARE complex.

  2002cites this paper
• X-ray Structure of a Neuronal Complexin-SNARE Complex from Squid*

  2002cites this paper